arrow
J

John Crown

school of bio technology
H指数:88
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

将口服可用的选择性雌激素受体降解剂与泛HER酪氨酸激酶抑制剂neratinib在HER2+/ER+乳腺癌的预临床模型中联合应用

2026-08-050
OA
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients

染色体着丝粒拷贝数扩增与HER2阳性转移性乳腺癌患者中的非凡反应相关

2025-12-200
OAAI
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆

HR阳性/HER2阴性早期乳腺癌患者的辅助瑞博西lib联合非甾体类芳香化酶抑制剂治疗:NATALEE试验5年随访的有效性结局及更新后的总生存期☆

2025-10-170
OAAI
Spontaneous regression of metastatic disease after palliative debulking surgery for heavily pre-treated extraskeletal myxoid chondrosarcoma: A case report

经姑息性减瘤术治疗的、先前接受过多线治疗的骨外黏液样软骨肉瘤发生转移性疾病的自发性消退:一例病例报告

2025-10-010
PRE
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

中间终点作为长期结局的替代指标在乳腺癌辅助化疗试验中的应用

2025-09-010
OAAI
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
2025-04-100
OAAI
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
2024-10-040
OAAI
Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) plus cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment

晚期黑色素瘤(不可切除/转移性 - aMel)患者(pts)接受fianlimab(FIAN)联合cemiplimab(CEMI)治疗后的长期随访:来自盲法独立中央评审(BICR)疗效评估的结果

2024-09-010
PRE
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE

来那替尼(RIB)联合非甾体类芳香化酶抑制剂(NSAI)在NATALEE研究中,对激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌(EBC)老年患者(pts)的疗效与安全性。

2024-09-011
PRE
Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
2024-05-020
PRE
Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
2024-05-023
PRE